FCAR and neoplasm: There is considerable research demonstrating that cross-linking of FcαR (CD89) using bispecific antibodies can induce tumor cytotoxicity [12–15], as well as target pathogens, such as Streptococcus pneumonia [16], Porphyromonas gingivalis [17], and Bordetella pertussis [18].